Mindset Pharma Inc. is a Canada-based drug discovery and development company. The Company is engaged in the psychedelic-based drug discovery business focused on creating patentable psychedelic compounds for the treatment of neurological and psychiatric disorders. Its drug development platform seeks to advance medicines based on psychedelic substances through rigorous scientific and clinical trials, performed by third-party contract research organizations. The Company has developed 4 families of next-generation psychedelics with differentiated characteristics. The Company's portfolio consists of macrodosing and microdosing. Its macrodosing includes Family 1/MSP-1014, Family 2, and Family 4. The MSP-1014 is a new chemical entity that incorporates a conjugated amplifier into a psilocybin-like structure to create an effective drug. The Company's Family 3 is a long-acting next-generation psychedelic drug positioned for micro-dosing.
Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.